Javier Gavira Díaz: New study published in the European Journal of Cancer
Javier Gavira Díaz, Specialist in oncology at Catalan Institute of Oncology (ICO), shared on LinkedIn about a recent article published in EJC:
“New study published in the European Journal of Cancer!
This EU multicenter study evaluated the activity of lenvatinib in 133 previously treated patients with metastatic RCC kidney cancer.
Key findings:
- Lenvatinib showed significant activity across different regimens, with nearly 30% objective responses.
- More than 25% of patients remained on treatment for at least 12 months, while 35% required dose adjustments.
- It also demonstrated efficacy after immunotherapy and TKI in refractory RCC.
Huge thanks to all the authors, authorities, and patients from three countries who made this study possible 🇫🇷 🇪🇸 🇬🇧.
A special thanks to Prof. Laurence Albiges and Dr. Ronan Flippot from Gustave Roussy for their mentorship and support, as well as the DUERTECC program, which allowed me to undertake a research fellowship at this incredible institution. Thank you very much for this unique opportunity.”
Authors: Javier Gavira et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023